All In Biotech

Drug Trial Radar · NCT02604433

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia

A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia

Last checked: Nov 20, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 336 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

336

Actual

Start

May 2, 2016

Primary completion

Jan 5, 2021

Study completion Jan 5, 2021

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
First posted
Nov 13, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) plus Best supportive care (BSC) versus placebo plus BSC in adults who require regular red blood cell transfusion due to (β)-thalassemia. The study is divided into the following periods: * Historical Period, * Screening/Run-in Period, * Double-blind Treatment Period (48 weeks), * Double-blind Long-term Treatment Period, (at the investigator's discretion an additional 48 weeks), * Open-Label Phase post unblinding and upon Data Monitoring Committee positive recommendation * Post-treatment Follow-up Period

Conditions

  • Erythrocyte Transfusion
  • Beta-Thalassemia

Interventions

  • LuspaterceptDrug

    Subjects will start with luspatercept at 1 mg/kg dose level.

  • PlaceboOther

    Placebo, Subcutaneous, every 21 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved Erythroid Response - Week 13 to Week 24Time frame: Baseline: Day -83 to Day 1; Treatment: Weeks 13 to Week 24

Locations

76 sites in 15 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Los Angeles

    Los Angeles, California

  • Children's Hospital and Research Center at Oakland

    Oakland, California

  • Ann and Robert H Lurie Childrens Hospital of Chicago

    Chicago, Illinois

  • Boston Children's Hospital

    Boston, Massachusetts

  • Weill Cornell Medical College

    New York, New York

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Royal Prince Alfred Hospital

    Camperdown, Australia

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia

  • Mater Hospital Brisbane

    South Brisbane, Queensland, Australia

  • Royal Adelaide Hospital Institute of Medical and Veterinary Science

    Adelaide, South Australia, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia

  • University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD

    Plovdiv, Bulgaria

  • Specialized Hospital for Active Treatment of Haematological Diseases - Sofia

    Sofia, Bulgaria

  • Multiprofile Hospital for Active Treatment Sveta Marina EAD

    Varna, Bulgaria

  • University Health Network

    Toronto, Ontario, Canada

  • Hopital Henri Mondor

    Créteil, France

  • GH de Institut Catholique St. VincentHématologie

    Lille, France

  • Hopitaux de La Timone

    Marseille, France

  • Hospital of Necker

    Paris, France

  • Laiko General Hospital of Athens

    Ampelokipi - Athens, Greece

  • Local Institution - 405

    Ampelokipi - Athens, Greece

  • General Children's Hospital "Agia Sophia"

    Athens, Greece

  • General Hospital Georgios Gennimatas of Athens

    Athens, Greece

  • University General Hospital of Patras

    Rio Patras, Greece

  • Hippokration Hospital

    Thessaloniki, Greece

  • Local Institution - 404

    Thessaloniki, Greece

  • Soroka University Medical Centre

    Beersheba, Israel

  • Rambam Health Corporation

    Haifa, Israel

  • HaEmek Medical Center

    Haïfa (Afula), Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Hadassah Medical Center

    Jerusalem, Israel

  • Galilee Medical Center

    Nahariya, Israel

  • Rabin Medical Center

    Petah Tikva, Israel

  • Presidio Ospedaliero Antonio Perrino

    Brindisi, Italy

  • Universita degli Studi di Cagliari - ASL8

    Cagliari, Italy

  • Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna

    Ferrara, Italy

  • Ente Ospedaliero Ospedali Galliera - Centro della Microcitemia e delle Anemie Congenite

    Genoa, Italy

  • Fondazione Ca Granda IRCCS Ospedale Maggiore

    Milan, Italy

  • AORN A Cardarelli

    Naples, Italy

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.